An Office of Management and Budget regulation, still open for public comment, would let political appointees override peer review on federal research grants and could put nearly 5,000 ongoing clinical trials at risk.
A proposed White House rule would shift the final call on federal research grants from career scientists and outside peer reviewers to political appointees inside the agencies that fund medical studies. A new analysis from the science-advocacy group Stand Up for Science warns that as many as 5,000 ongoing clinical trials, including roughly 1,000 cancer studies and hundreds of pediatric, veteran, and heart-disease trials, could be terminated if the rule takes effect in its current form (Scientific American, June 16, 2026).
The trigger is a rule the Office of Management and Budget, the executive branch's budget and regulatory clearinghouse, put out for public comment in May 2026 (Federal Register docket OMB-2026-0034, "Regulation for Federal Financial Assistance"). The proposed regulation would give politically appointed officials at agencies such as the National Institutes of Health, the Department of Veterans Affairs, and the National Science Foundation the final word on which research grants get approved, renewed, or cut. Under the current system, outside scientists score applications on merit in a process called peer review; the agencies then fund the strongest proposals. The OMB rule would not replace peer review, but it would let a political appointee override its outcome.
OMB's own statement framing the rule describes its goal as eliminating what it calls "a woke policy agenda" in research and reducing "international collaboration" that, in the administration's telling, diverts federal science dollars from domestic priorities. That language is administration framing, not an independent finding, and it helps explain the kind of decisions the rule is designed to enable. Russell Vought, the OMB director, is the named architect of the proposal and is identified by news organizations including the Associated Press as a lead author of the Heritage Foundation's Project 2025 blueprint for the executive branch, which called for inserting political review into the grant pipeline.
The 5,000-trial figure is Stand Up for Science's own tally, drawn from its review of the clinical-trial registry. It is a single advocacy group's count, not an independent government estimate, and the group's methodology for deciding which trials would be terminated versus merely disrupted is described in general terms. The headline number is useful for sizing the stakes, and it should be read as the analysis Stand Up for Science says it is.
The human consequences are concrete. A cancer treatment trial that loses its federal funding mid-cycle cannot simply reopen at a later date; the patients enrolled have already consented, the dosing schedules are in motion, and the data the study was designed to collect is at risk of being thrown out. Pediatric trials face the same arithmetic with a smaller pool of eligible participants to begin with. Veteran-health studies often run only inside the VA system, leaving no obvious alternate funder.
The rule is not yet final. OMB has opened a public comment period, and the Federal Register docket OMB-2026-0034 specifies the comment deadline is July 13, 2026 — with more than 28,000 comments already submitted as of June 16. If implemented, the rules would take effect by October 2026. Once that window closes, OMB can revise, withdraw, or finalize the rule, and Congress can weigh in through oversight or appropriations. The comment period is the lever that exists right now.
The thing to watch next is the July 13 comment deadline itself, and the first batch of agency-level implementation guidance that follows. Agencies will have to write internal procedures for how a political appointee will actually weigh in on individual grant decisions, and those procedures will determine whether the override is rare or routine. If the answer is routine, the practical effect is that peer review stops being the binding constraint on what gets funded, and a political filter takes its place.